In Alzheimer’s disease, some microglia gather around plaques, while others seem aloof, opting to keep their distance. In the July 14 Nature Neuroscience, scientists led by Marco Prinz at the ...

Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Geneticists combined AD and AD-by-proxy datasets to search for risk variants in diverse cohorts. Sixteen novel AD-associated loci cropped up in meta-analyses. Few loci identified in clinical AD ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...

For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and ...

With several fluid biomarkers for Alzheimer’s in hand, the search is on for counterparts in Parkinson’s disease and dementia with Lewy bodies (DLB). Four new papers introduce two candidates: DOPA ...